Lipoprotein oxidation biomarkers for cardiovascular risk: What does the future hold?

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 4, 2012, Pages 399-402

  Taleb, Adam ^a   Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

autoantibodies; cardiovascular disease; LDL; Lp(a); oxidation biomarkers; oxidized phospholipids

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; PHOSPHOLIPASE A2; PHOSPHOLIPID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HEART DEATH; HEART INFARCTION; HUMAN; OXIDATION KINETICS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; STROKE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; RISK FACTORS;

EID: 84859458291     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.32     Document Type: Review

References (22)

1. Ravandi A, Boekholdt SM, Mallat Z et al. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: Results from the EPIC-Norfolk Study. J. Lipid Res. 52, 1829-1836 (2011).
2. Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 120, 417-426 (2009).
3. Miller YI, Choi SH, Wiesner P et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ. Res. 108, 235-248 (2011).
4. Amir S, Hartvigsen K, Wagner O, Tsimikas S, Witztum JL, Binder CJ. Peptides isolated from a peptide phage display library mimic an epitope of MDA-LDL and apoptotic cells and are recognized by human autoantibodies. Circulation 124, A16597 (2011).
5. Hartvigsen K, Chou MY, Hansen LF et al. The role of innate immunity in atherogenesis. J. Lipid Res. 50(Suppl.), S388-S393 (2009).
6. Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on apolipoprotein B-100 (OxPL/apoB) containing lipoproteins: A biomarker predicting cardiovascular disease and cardiovascular events. Biomarkers Med. 5, 673-694 (2011).
7. Itabe H, Ueda M. Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J. Atheroscler. Thromb. 14, 1-11 (2007).
8. Rosenson RS. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc. Drugs Ther. 23, 93-101 (2009).
9. Kiechl S, Willeit J, Mayr M et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: Prospective results from the Bruneck study. Arterioscler. Thromb. Vasc. Biol. 27, 1788-1795 (2007). (Pubitemid 47207175)
10. Tsimikas S, Willeit P, Willeit J et al. Oxidation-specific biomarkers and prospective 15-year cardiovascular and stroke outcomes. J. Am. Coll. Cardiol. (2012) (Abstract).
11. Tsimikas S, Mallat Z, Talmud PJ et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J. Am. Coll. Cardiol. 56, 946-955 (2010).
12. Tsimikas S, Brilakis ES, Miller ER et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 353, 46-57 (2005). (Pubitemid 41007806)
13. Raal FJ, Santos RD, Blom DJ et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial. Lancet 375, 998-1006 (2010).
14. Merki E, Graham M, Taleb A et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J. Am. Coll. Cardiol. 57, 1611-1621 (2011).
15. Weismann D, Hartvigsen K, Lauer N et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478, 76-81 (2011).
16. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301, 2331-2339 (2009).
17. Clarke R, Peden JF, Hopewell JC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518-2528 (2009).
18. Davidson MH, Ballantyne CM, Jacobson TA et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. J. Clin. Lipidol. 5, 338-367 (2011).
19. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur. Heart J. 31, 2844-2853 (2010).
20. Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A in cardiovascular disease: Roles as biological effectors and biomarkers. Circulation 122, 2183-2200 (2010).
21. Thompson A, Gao P, Orfei L et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies. Lancet 375, 1536-1544 (2010).
22. Ryu SK, Mallat Z, Benessiano J et al. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation 125, 757-766 (2012).